These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 35437217)

  • 21. Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies.
    Gallagher KM; Christopher E; Cameron AJ; Little S; Innes A; Davis G; Keanie J; Bollina P; McNeill A
    BJU Int; 2019 Mar; 123(3):429-438. PubMed ID: 30113755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline prostate health index risk category and risk category changes during active surveillance predict grade reclassification.
    de la Calle CM; Jing Y; Mamawala MM; Landis P; Macura KJ; Trock BJ; Epstein JI; Sokoll LJ; Pavlovich CP
    Urol Oncol; 2023 Nov; 41(11):455.e1-455.e6. PubMed ID: 37722985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
    Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
    Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MRI at diagnostic versus confirmatory biopsy during MRI-based active surveillance of prostate cancer.
    Marras M; Ellis JL; Copelan O; Naha U; Han T; Rac G; Quek ML; Gorbonos A; Woods ME; Flanigan RC; Gupta GN; Patel HD
    Urol Oncol; 2024 Oct; 42(10):331.e1-331.e6. PubMed ID: 38890040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
    Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply?
    Hu JC; Chang E; Natarajan S; Margolis DJ; Macairan M; Lieu P; Huang J; Sonn G; Dorey FJ; Marks LS
    J Urol; 2014 Aug; 192(2):385-90. PubMed ID: 24512956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in Magnetic Resonance Imaging Using the Prostate Cancer Radiologic Estimation of Change in Sequential Evaluation Criteria to Detect Prostate Cancer Progression for Men on Active Surveillance.
    O'Connor LP; Wang AZ; Yerram NK; Long L; Ahdoot M; Lebastchi AH; Gurram S; Zeng J; Harmon SA; Mehralivand S; Merino MJ; Parnes HL; Choyke PL; Shih JH; Wood BJ; Turkbey B; Pinto PA
    Eur Urol Oncol; 2021 Apr; 4(2):227-234. PubMed ID: 33867045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validating the total cancer location density metric for stratifying patients with low-risk localized prostate cancer at higher risk of grade group reclassification while on active surveillance.
    Tan GH; Deniffel D; Finelli A; Wettstein M; Ahmad A; Zlotta A; Fleshner N; Hamilton R; Kulkarni G; Nason G; Ajib K; Herrera-Caceres J; Chandrasekar T; Perlis N
    Urol Oncol; 2023 Mar; 41(3):146.e23-146.e28. PubMed ID: 36639336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors predicting prostate cancer upgrading on magnetic resonance imaging-targeted biopsy in an active surveillance population.
    Lai WS; Gordetsky JB; Thomas JV; Nix JW; Rais-Bahrami S
    Cancer; 2017 Jun; 123(11):1941-1948. PubMed ID: 28140460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE).
    Klotz L; Chin J; Black PC; Finelli A; Anidjar M; Machado A; Levental M; Ghai S; Chang SD; Patel C; Kassam Z; Loblaw A; Kebabdjian M; Pond G; Haider MA
    Eur Urol Oncol; 2024 Jun; 7(3):456-461. PubMed ID: 37838556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL.
    Lee DH; Nam JK; Park SW; Lee SS; Han JY; Lee SD; Lee JW; Chung MK
    Yonsei Med J; 2016 May; 57(3):565-71. PubMed ID: 26996553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic Resonance Imaging-guided Active Surveillance Without Annual Rebiopsy in Patients with Grade Group 1 or 2 Prostate Cancer: The Prospective PROMM-AS Study.
    Valentin B; Arsov C; Ullrich T; Al-Monajjed R; Boschheidgen M; Hadaschik BA; Giganti F; Giessing M; Lopez-Cotarelo C; Esposito I; Antoch G; Albers P; Radtke JP; Schimmöller L
    Eur Urol Open Sci; 2024 Jan; 59():30-38. PubMed ID: 38298772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
    Kearns JT; Faino AV; Newcomb LF; Brooks JD; Carroll PR; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y; Lin DW
    Eur Urol; 2018 May; 73(5):706-712. PubMed ID: 29433973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.
    Singh S; Sandhu P; Beckmann K; Santaolalla A; Dewan K; Clovis S; Rusere J; Zisengwe G; Challacombe B; Brown C; Cathcart P; Popert R; Dasgupta P; Van Hemelrijck M; Elhage O
    BJU Int; 2021 Jul; 128(1):72-78. PubMed ID: 33098158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of Multi-Parametric Magnetic Resonance Image and PIRADS Score in Patients with Prostate Cancer Eligible for Active Surveillance According PRIAS Criteria.
    Almeida GL; Petralia G; Ferro M; Ribas CA; Detti S; Jereczek-Fossa BA; Matei DV; Coman I; De Cobelli O; Tagliabue E
    Urol Int; 2016; 96(4):459-69. PubMed ID: 27045167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial.
    Schiavina R; Droghetti M; Novara G; Bianchi L; Gaudiano C; Panebianco V; Borghesi M; Piazza P; Mineo Bianchi F; Guerra M; Corcioni B; Fiorentino M; Giunchi F; Verze P; Pultrone C; Golfieri R; Porreca A; Mirone V; Brunocilla E
    Urol Oncol; 2021 Jul; 39(7):433.e1-433.e7. PubMed ID: 33191117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
    Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
    J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging-directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve Men.
    Wagensveld IM; Osses DF; Groenendijk PM; Zijta FM; Busstra MB; Rociu E; Barentsz JO; Michiel Sedelaar JP; Arbeel B; Roeleveld T; Geenen R; Koeter I; van der Meer SA; Cappendijk V; Somford R; Klaver S; Van der Lely H; Wolters T; Hellings W; Leter MR; Van der Poel HG; Heijmink SWTPJ; Debruyne F; Immerzeel J; Leijte J; van Roermund J; Miclea R; Planken E; Vis AN; Jan de Jong I; Tijsterman J; Wolterbeek D; Claessen A; Vrijhof E; Nederend J; Van Leenders GJLH; Bangma CH; Krestin GP; Remmers S; Schoots IG;
    Eur Urol; 2022 Sep; 82(3):318-326. PubMed ID: 35341658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
    Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF
    Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.